The Food and Drug Administration approved an expanded use of Boehringer Ingelheim's asthma drug tiotropium Respimat.
Tiotropium Respimat is an inhaled corticosteroid drug patients administer once daily through Boehringer Ingelheim's Respimat inhaler.
The FDA first approved the drug in 2015 for asthma patients age 12 and older. Now, the drug can also be used to treat children ages six and up.
More articles on supply chain:
4 thoughts from Trump's CMS pick on reducing federal drug spending
Prime Therapeutics reports 2.5% increase in drug spending for 2016
FDA approves Valeant's psoriasis drug